Table 2.
Comparison of clinical and laboratory features between patients with intermediate-risk AML low and high expression.
| Patient parameters | Intermediate-risk AML | ||
|---|---|---|---|
| POU5F1Blow (n=78) | POU5F1Bhigh (n=20) | P value | |
| Sex, Male/Female | 49/29 | 13/7 | 1.000 |
| Median age, years (range) | 61 (20–93) | 57 (21–83) | 0.038 |
| Median WBC, ×109/L (range) | 21.3 (0.4–528.0) | 7.7 (0.3–203.6) | 0.129 |
| Median hemoglobin, g/L (range) | 81.5 (32.0–144.0) | 77.5 (34.0–131.0) | 0.988 |
| Median platelets, ×109/L (range) | 42.5 (3.0–399.0) | 52.5 (4.0–415.0) | 0.547 |
| BM blasts,% (range) | 55.0 (21.5–99.0) | 48.5 (6.0–93.0) | 0.506 |
| CR (+/−) | 20/52 | 11/8 | 0.027 |
| FAB | 0.883 | ||
| M0 | 1 | 1 | |
| M1 | 6 | 1 | |
| M2 | 39 | 9 | |
| M3 | 1 | 0 | |
| M4 | 17 | 5 | |
| M5 | 11 | 3 | |
| M6 | 3 | 1 | |
| Gene mutation | |||
| CEBPA (+/−) | 11/57 | 3/14 | 1.000 |
| NPM1 (+/−) | 11/57 | 4/13 | 0.487 |
| FLT3-ITD (+/−) | 10/58 | 2/15 | 1.000 |
| c-KIT (+/−) | 1/67 | 1/16 | 0.362 |
| NRAS or KRAS (+/−) | 7/61 | 3/14 | 0.411 |
| IDH1/2 (+/−) | 5/63 | 1/16 | 1.000 |
| IDH2 R140(+/−) | 3/65 | 1/16 | 1.000 |
| DNMT3A (+/−) | 9/59 | 0/17 | 0.194 |
| U2AF1 (+/−) | 4/64 | 1/16 | 1.000 |
| SRSF2 (+/−) | 6/64 | 0/17 | 0.593 |